TYMS and colorectal cancer: Indeed, in a phase I clinical trial of 12 patients with metastatic, refractory colorectal cancer treated with the combination of ATO and 5-FU[36], correlative studies demonstrated that ATO caused a significant decrease in thymidylate synthase mRNA levels in peripheral blood mononuclear cells.